BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
June 21, 2011
View Archived Issues
New clinical data presented on brentuximab vedotin
Read More
Selective ROCK-2 inhibitors presented by University of Michigan
Read More
Targeted secretion inhibitors SXN-101000 and SXN-101742 inhibit growth hormone secretion in vivo
Read More
Aliskiren shows efficacy in children with hypertension
Read More
New GPR119 receptor agonists claimed by Pfizer
Read More
Researchers at GSK present new antimalarial agents
Read More
Novel muscarinic acetylcholine M1 receptor modulators disclosed
Read More
Merck KGaA presents new HSP 90 inhibitors
Read More
Cubist Pharmaceuticals reports phase II data on CXA-201 and CB-183315
Read More
FDA committee recommends approval of VEGF Trap-Eye for wet AMD
Read More
Photocure begins enrolling women with CIN due to HPV infection in phase II Cevira trial
Read More
Yeast-based vaccine GI-6207 is safe in phase I trial in metastatic cancer expressing CEA
Read More
Fostamatinib disodium improves quality of life in subjects with active rheumatoid arthritis
Read More
Pentraxin-related protein PTX3 described as novel biomarker in advanced pancreatic cancer
Read More
Takeda begins phase III study of TAK-816 vaccine in Japan
Read More
Sunshine Biopharma and the Jewish General Hospital to collaborate on Adva-27a
Read More
National Eye Institute awards grant to Cedars-Sinai to develop stem cell therapies
Read More
LMS-611 obtains European orphan drug status in cystic fibrosis
Read More
Azellon to conduct phase I stem cell trial in the U.K. for meniscal tears
Read More
Wilex provides update on the Redectane approval process
Read More
Theratechnologies seeks approval for Egrifta in Canada
Read More
NovaBay and Alcon terminate Aganocides collaboration and license agreement
Read More
GTx begins phase IIb trial comparing Capesaris to Lupron Depot in advanced prostate cancer
Read More
FDA approves new 6-month formulation of Lupron Depot for advanced prostate cancer
Read More
Chelsea Therapeutics reports encouraging results from QTc interval study of Northera
Read More